Healthcare and Pharmaceutical Market Research Reports: August 2023

Thursday 31 August 2023

Digital Health Industry Data Book | Analysis, Trends, Outlook, and Research Report to 2030

Digital Health Industry Data Book

The global digital health market size was valued at USD 211.0 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 18.6% from 2023 to 2030.

The digital health industry data book, compiled by Grand View Research, is a collection of market sizing information & forecasts, trade data, pricing intelligence, competitive benchmarking analyses, macro-environmental analyses, and regulatory & technological framework studies. Within the purview of the database, such information is systematically analyzed and provided in the form of outlook reports and summary presentations on individual areas of research along with a digital healthcare statistics e-book.

Tele-Healthcare Market Insights

The global telehealth market size was valued at USD 87.6 billion in 2022 and is projected to expand at a compound annual growth rate (CAGR) of 23.5% from 2023 to 2030. The rising penetration of the internet and innovation in smartphones is enabling to address the gaps in the delivery and availing of telehealth services conveniently. Moreover, the demand for telehealth services witnessed tremendous growth over the past year due to the COVID-19 pandemic and the restrictions imposed to curb the infection. COVID-19 hindered the delivery of healthcare services, which enabled most healthcare facilities to shift from traditional to virtual care methods. Furthermore, the growing need to monitor health and wellness to manage chronic diseases virtually is driving the industry's growth.

mHealth Market Insights

The global mHealth market size was valued at USD 56.8 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 10.8% from 2023 to 2030. The rising focus on improving personal health and fitness using smart devices and wearables is the major factor accelerating market growth. Besides, increasing penetration of the internet and smartphones and growing adoption of mHealth technology and platforms by physicians and patients are also anticipated to propel market growth.

Shifting trend of adopting patient centric and preventive approaches from conventional healthcare practices are also expected to drive the market growth. For instance, as per the statistics published in a digital health journal in 2020, about 64% approved on the benefit of tracking medical treatment, and 68% of users agreed that the apps which retrieve EMR remotely are highly valuable for a healthy lifestyle. Increasing investment by government and non-government organizations in expanding digital healthcare sector further boosts the market growth.

Order your copy of the Free Sample of “Digital Health Industry Data Book - Tele-Healthcare, mHealth, Healthcare Analytics and Digital Health System Market Size, Share, Trends Analysis, And Segment Forecasts, 2022 - 2030” Data Book, published by Grand View Research

Healthcare Analytics Market insights

The global healthcare analytics market size was valued at USD 35.3 billion as of 2022 and is expected to expand at a compound annual growth rate (CAGR) of 21.4% from 2023 to 2030. The healthcare industry on the whole has been challenged with the issues like lack of better patient care, skyrocketing costs of treatment, less patient retention, and engagement and, thus healthcare analytics are being incorporated into every aspect of the industry to give better care to patients and for better operations of the industry. These factors are key reasons for the growth of the healthcare analytics industry.

New advanced analytics tools and services are being introduced, which, in turn, is driving their adoption by healthcare organizations. For instance, in September 2020, Eversana launched predictive analytics solution, ACTICS. Similarly, in June 2021, QPharma opened Neolytica, a firm that provides AI-based predictive analytics solutions. Development of new advanced analytics technologies and methods with increasing awareness about benefits of analytics is another major factor expected to drive the market.

Digital Health System Market Insights

The global digital health market size was valued at USD 211.0 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 18.6% from 2023 to 2030. Increasing penetration of smartphones, improved internet connectivity with the introduction of 4G/5G, advancement in healthcare IT infrastructure, rising need to curb healthcare costs, rising prevalence of chronic diseases, and the increase in accessibility of virtual care are some of the major factors to fuel the market growth. Furthermore, key players focus on introducing advanced applications to improve user experience. For instance, in July 2021, Teladoc Health collaborated with Microsoft to integrate its Solo platform with the Microsoft Teams environment to improve clinician and patient access across the virtual healthcare space.

Government initiatives to spread digitalization across the healthcare sector throughout the globe are further driving the market. For instance, during the 2022 budget session, the Government of India introduced a digital health ecosystem under Ayushman Bharat Digital Health Mission (ABDM). Similarly, in October 2021, France government announced that they will invest over USD 650 million to expand their digital health infrastructure on a national level.

Go through the table of content of Digital Health Industry Data Book to get a better understanding of the Coverage & Scope of the study.

Digital Health Industry Data Book Competitive Landscape

Increasing demand for technologically advanced digital health platforms and services are increasing competition in the market and thus, forcing key players to introduce new solutions in the market. Additionally, it is projected that rising industry consolidation activities, such as acquisitions and mergers by the leading market participants, as well as expanding efforts in R&D of digital health applications by key players, is also expected to boost the market share.

Key players operating in the Digital Health Industry are –

• Apple Inc.
• AT&T
• AirStrip Technologies
• Allscripts
• Google Inc.
• Orange
• Qualcomm Technologies, Inc.
• Softserve
• MQure
• Samsung Electronics Co., Ltd.
• Telefónica S.A.
• Vodafone Group
• Cerner Corporation
• McKesson Corporation
• Epic Systems Corporation
• NextGen Healthcare, Inc. (QSI Management, LLC)
• Greenway health, LLC
• CureMD Healthcare
• HiMS
• Computer Programs and Systems, Inc.
• Vocera Communications
• IBM Corporation (IBM Watson Health)
• Siemens Healthcare GmbH
• CISCO Systems, Inc.

Check out more Industry Data Books, published by Grand View Research

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com/sector-reports-list

Wednesday 30 August 2023

Healthcare 3D Printing Industry To Rise Because Of Intervention Of Government For Improving Healthcare Infrastructure And Increasing Investments In The R&D Sector

The healthcare 3D printing industry was valued at USD 9.4 billion in 2022 and is estimated to witness a CAGR of 17.0% over the forecast period. Factors like the shortage of available organs for transplantation globally and the emergence of digital healthcare are expected to drive the market over the forecast period.

Access the Global Healthcare 3D Printing Industry Data Book, 2023 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competitive benchmarking, macro-environmental analyses, and regulatory & technological framework studies.

Healthcare Additive Manufacturing Market Growth & Trends

The global healthcare additive manufacturing market size is expected to reach USD 27.3 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 18.1% from 2023 to 2030. Healthcare additive manufacturing technology aids in making complex designs easily, developing personalized products, reducing production steps, and producing lightweight products, which fuels market growth.

Growing commercialization of the manufacturing process, rising investments by governments, and increased R&D in devices formed using additive manufacturing technology are key factors driving this market. There was a slowdown in the growth of the market at the start of 2020 due to the COVID-19 outbreak, but the market gained pace in the second half of the year by fulfilling the growing demand for the manufacturing of medical devices, PPE kits, and face shields to fight against the pandemic.

The advantages of additive manufacturing over traditional production methods are boosting its rising popularity. The use of modern design freedom, technology, dimensional precision, the use of a wide range of materials such as plastics, metal, and polymers, build speed, and the capacity to construct complicated parts/geometry, such as honeycomb structure and cooling channels, are some of the advantages of additive manufacturing.

3D Bioprinting Market Growth & Trends

The global 3D bioprinting market size is expected to reach USD 5.3 billion by 2030, expanding at a CAGR of 12.5% over the forecast period, according to a new report by Grand View Research, Inc. Rising cases of COVID-19 and high prevalence of chronic diseases are some of the major factors contributing to the growth. During the outbreak of the pandemic, 3D printing has stepped up to become a vital technology to support improved healthcare and emergency response.

The COVID-19 epidemic is ever increasing since it was first identified in China in December 2019. Until January 12, 2021, more than 91.5 million cases of COVID-19 were reported globally, with more than 1,956,880 deaths, across the globe. This pandemic has fast-tracked the development of vaccine and drug testing.

In the meantime, various 3D bioprinting companies are focused on the R&D of artificial tissues. With the help of U-FAB and other bioprinting technologies, CLECELL company has created respiratory epithelium artificial tissue which will help to prevent infection and tissue injury through the use of the mucociliary elevator.

Order your copy of Free Sample of “Healthcare 3D Printing Industry Data Book - Healthcare Additive Manufacturing, 3D Bioprinting and 3D Printed Drugs Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

3D Printed Drugs Market Growth & Trends

The global 3D printed drugs market is expected to reach USD 269.74 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 15.32% from 2022 to 2030. The rising prevalence of chronic diseases, combined with the rising population of patients with dysphagia around the globe is pushing the demand for immediate soluble medications, which is likely to drive the market. For instance, according to a study published in April 2022, the prevalence of oropharyngeal dysphagia is high in conditions such as stroke and aging and is reported to be 26.19% in the elderly.

An increase in the aging population has led to the growing demand for the development of easy-to-swallow pills for the elderly. The 3D printed highly soluble and easy-to-swallow drugs can help the elderly who have difficulty swallowing. Moreover, according to the United Nations, the number of people aged 65 and more in 2050 is projected to be 1.5 billion. Thus, the growing elderly population across the world would propel the demand for easy-to-swallow drugs resulting in market growth.

Other factors such as quickly expanding demand for pharmaceuticals, technical improvements in healthcare, as well as the government's focus and expenditures in the 3D printing industry, are also contributing to the market's growth. For instance, in March 2022, Evonik Venture Capital invested in Nevada-based Laxxon Medical for the manufacturing of 3D-printed tablets. The latter company has developed a 3D screen-printing technology for the production of structured tablets with the controlled release of API over time. Such investments are likely to supplement the market growth in the coming years.

The COVID-19 pandemic is anticipated to positively impact market growth. Several printers have been launched by the operating companies in the advanced manufacturing industry to help increase the manufacturing of medications and other necessary products. As a result, the usage of these technologies is projected to increase during the COVID-19 pandemic.

Go through the table of content of Healthcare 3D Printing Industry Data Book to get a better understanding of the Coverage & Scope of the study.

Competitive Landscape

Key players operating in the Healthcare 3D Printing Industry are –

• 3D Systems, Inc.
• EnvisionTEC
• Stratasys Ltd.
• Allevi, Inc.
• GE Healthcare
• Nanoscribe GmbH
• Materialise N.V.
• Cyfuse Biomedical
• RegenHU
• Renishaw

Grand View Research’s Healthcare 3D Printing industry data book is a collection of market sizing information & forecasts, regulatory data, competitive benchmarking analyses, macro-environmental analyses, and technological framework studies. Within the purview of the database, all such information is systematically analyzed and provided in the form of presentations and detailed outlook reports on individual areas of research.

Check out more Industry Data Books, published by Grand View Research

About Grand View Research

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com/sector-reports-list

Friday 18 August 2023

Female Infertility Industry To Grow Up Due To Increasing The Number Of Women Seeking IVF Treatment

Female Infertility Industry Data Book

Female Infertility Industry Data Book Covers In Vitro Fertilization (IVF) and Artificial Insemination Markets.

The global female infertility market size was valued at USD 25.7 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5.97% from 2023 to 2030.

Access the Global Female Infertility Industry Data Book, 2023 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competitive benchmarking, macro-environmental analyses, and regulatory & technological framework studies.

In Vitro Fertilization Market Growth & Trends

The global in vitro fertilization market size is expected to reach USD 37.4 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.72% from 2023 to 2030. The market is driven by the continuous efforts of the market players, government initiatives to make available better reimbursement policies, and an increase in the incidence of infertility due to lifestyle changes. The expansion of fertility procedures such as ICSI for treating infertility is expected to positively impact market growth in the near future.

Moreover, the availability of genomic testing facilities that enable the prevention of the transfer of genetic disorders during In Vitro Fertilization (IVF) is further expected to drive the IVF market. The insurance providers are providing coverage for IVF procedures owing to an increase in the number of IVF treatments. This has led to competitive pricing and has moderated the IVF treatment costs as the procedure has been a successfully practiced technology, driving the market with more treatment automation and standardization.

A decline in the Total Fertility Rate (TFR) is a result of factors such as a behavioral shift in society. These factors include a shift from rural to urban societies, the increased age of the first birth, postponement of marriage, an increasing number of women employees, and lower marriage rates. In March 2020, in-person fertility treatments in U.S. and Canada were suspended due to COVID-19 by the American Society of Reproductive Medicine and Canadian Fertility and Andrology Society. However, treatment is resuming in many countries with the ease of COVID-19 restrictions. The research findings published by the Obstetrics and Gynecology journal, in January 2022 reported COVID-19 vaccines won't harm IVF outcomes. This is expected to prove significant in promoting the uptake of IVF in eligible vaccinated individuals.

Order your copy of Free Sample of “Female Infertility Industry Data Book - In Vitro Fertilization (IVF) and Artificial Insemination Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

Artificial Insemination Market Growth & Trends

The global artificial insemination market size is expected to reach USD 2.9 billion by 2026 registering a CAGR of 8.4%, according to a new report by Grand View Research, Inc. Over the past few years, infertility has become a major public health concern across the globe. Artificial insemination is usually the preferred first-line treatment to tackle infertility. Lifestyle changes, delay in pregnancy, and hormonal issues are some of the reasons contributing to the rise in fertility-related problems. According to the United Nations, the global fertility rate is expected to decline to 2.2% by 2050. In developing or underdeveloped nations, medical consultation regarding infertility was not easily accessible.

Hence, there was a lack of awareness about available assisted reproductive techniques including artificial or donor insemination and IVF. The average cost of performing an IUI is around USD 865. The success rate for each cycle is around 4 to 5%, which can be increased to about 7 to 16% by consuming fertility drugs. However, older women are not encouraged to go through IUI due to slim chances of success and further complications. Several fertility problems can be addressed through IUI, such as semen allergy, unexplained infertility, and Sexually Transmitted Diseases (STDs).

Go through the table of content of Female Infertility Industry Data Book to get a better understanding of the Coverage & Scope of the study.

Competitive Landscape

Key players operating in the Female Infertility Industry are –

• Ferring B.V.
• Vitrolife AB
• CooperSurgical, Inc.
• Cosmos Biomedical Ltd.
• Merck KGaA
• Cryolab Ltd.
• FUJIFILM Irvine Scientific
• Bloom IVF Centre
• Microm UK Ltd.
• OvaScience
• Irvine Scientific
• Progyny, Inc.
• EMD Serono Inc.
• Thermo Fisher Scientific Inc.
• Boston IVF

Grand View Research’s Female Infertility industry data book is a collection of market sizing information & forecasts, regulatory data, competitive benchmarking analyses, macro-environmental analyses, and technological framework studies. Within the purview of the database, all such information is systematically analyzed and provided in the form of presentations and detailed outlook reports on individual areas of research.

Check out more Industry Data Books, published by Grand View Research

About Grand View Research

Diagnostic Imaging Industry To Rise Due To Growing Prevalence Of Chronic Disorders And Technological Advancements Till 2030

Diagnostic Imaging Industry Data Book Covers Computed Tomography, Magnetic Resonance Imaging, Nuclear Imaging, Ultrasound Device and X-ray Systems Markets.

Grand View Research’s diagnostic imaging industry data book is a collection of market sizing information & forecasts, regulatory data, reimbursement structure, competitive benchmarking analyses, macro-environmental analyses, and regulatory & technological framework studies. Within the purview of the database, all such information is systematically analyzed and provided in the form of presentations and detailed outlook reports on individual areas of research.

Access the Global Diagnostic Imaging Industry Data Book, 2023 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competitive benchmarking, macro-environmental analyses, and regulatory & technological framework studies.

Computed Tomography Market Growth & Trends

The global computed tomography market size is expected to reach USD 7,551.7 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.3% from 2022 to 2030. The increasing burden of chronic disorders, such as cardiovascular diseases and cancer, and the high demand for effective imaging tools are the factors driving growth. According to the International Agency for Cancer on Research, in 2020 globally there were about 19,292,789 new cancer cases with 9,958,133 deaths. The same source stated that the prevalence of cancer is predicted to increase to 50,550,287 by 2025. In addition, increasing demand for computed tomography (CT) systems in emergency care departments are expected to be a major driver during the forecast period.

Advanced technology with features such as dose management systems, the ability to diagnose tumors through motion (4D), artificial intelligence integration, and high-end material differentiation is expected to replace the existing conventional devices. In September 2021, GE Healthcare introduced the Revolution Ascend CT system, the technology that combines artificial intelligence (AI) to improve operational efficiency and patient comfort. The increasing number of favorable reimbursement policies by the government as well as private entities are also expected to drive the market at a lucrative pace. Growing demand for ambulatory diagnostic centers due to improving affordability and increasing reach of CT scanners to remote regions is expected to aid further growth.

Magnetic Resonance Imaging Market Growth & Trends

The global magnetic resonance imaging market size is expected to reach USD 9.1 billion by 2030, registering a CAGR of 6.8% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of chronic diseases and increasing demand for early diagnostic techniques are the factors expected to drive the market growth.
In addition, the growing adoption of less invasive procedures is also contributing to the growth of the market. Moreover, the growing number of clinical trials to understand the effectiveness and efficiency of MRI machines in various clinical applications is also expected to boost the market growth. End-users such as research institutes and universities are frequently studying the efficiency of MRI devices with high field strength such as 7T, 10T, and 10.5T.

Order your copy of Free Sample of “Diagnostic Imaging Industry Data Book - Computed Tomography, Magnetic Resonance Imaging, Nuclear Imaging, Ultrasound Device and X-ray Systems Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

Ultrasound Device Market Growth & Trends

The global ultrasound device market size is expected to reach USD 14.5 billion by 2030, registering a CAGR of 4.3% over the forecast period, according to a new report by Grand View Research, Inc. Ultrasound is a very efficient technology that aids in the diagnosis of various disorders such as tumors as well as the detection of changes in the appearance of organs, tissues, and arteries. It also has a range of therapeutic applications. An increase in the adoption of ultrasound devices for diagnosis and treatment is driving the market. In addition, a rise in the adoption of minimally invasive surgeries, coupled with technological advancements is expected to boost the market growth.

Emerging innovations in ultrasound technology are expanding the market size. Hand-held ultrasound devices have made the technology more accessible for use in limited-resource communities around the world. Furthermore, the introduction of 3D/4D ultrasound and the integration of artificial intelligence (Al) to automate time-consuming processes are expected to propel the market growth during the forecast period. For instance, in September 2020, GE Healthcare launched Voluson SWIFT, a new ultrasound technology, which is designed to help women’s health by allowing clinicians to enhance patient outcomes by expanding diagnostic capabilities. The system includes industry-first AI algorithms for auto-recognition and has excellent image quality.

X-ray Systems Market Growth & Trends

The global x-ray systems market size is expected to reach USD 9.4 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 2.3% from 2022 to 2030. Technological advancements in the healthcare sector and supportive investments by the government are driving the market. In addition, increase in the demand for early-stage diagnosis of chronic diseases and screening programs are expected to boost market growth.

Emerging innovations in the x-ray systems is expanding the market size, such as integration of Artificial Intelligence (AI) in medical imaging systems, robotic, and mobile x-ray systems have made the technology more accessible for use in limited-resource communities around the world. For instance, in March 2021, Philips healthcare announced partnership with Lunit, a leading medical AI startup, with this collaboration Lunit’s INSIGHT CXR chest detection suite will be incorporated into Philips diagnostic x-ray suite, to achieve better patient outcomes, improve the experience of patients and staff, and lower the cost of care.

The rising prevalence and awareness of chronic diseases like cancer, neurological conditions, orthopedics and cardiovascular diseases, which demands the adoption of x-ray systems for diagnosis are expected to expand the market during forecast period. Furthermore, the growing adoption of Digital Radiography (DR) is expected to boost the market growth as DR systems produces, high contrast resolution images at a lower ionizing radiation.

Go through the table of content of Diagnostic Imaging Industry Data Book to get a better understanding of the Coverage & Scope of the study.

About Grand View Research

Thursday 17 August 2023

Clinical Laboratory Industry To Grow Up Due To Developing Chronic Diseases Over The Forecast Period

Clinical Laboratory Industry Data Book Covers Clinical Laboratory Tests and Clinical Laboratory Service Markets.

The global clinical laboratory markets combine to account for USD 321.20 billion in revenue in 2022, which is expected to reach USD 493.72 billion by 2030, growing at a cumulative rate of 5.52% over the forecast period.

Access the Global Clinical Laboratory Industry Data Book, 2023 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competitive benchmarking, macro-environmental analyses, and regulatory & technological framework studies.

Clinical Laboratory Tests Market Growth & Trends

The global clinical laboratory tests market size is expected to reach USD 213.04 billion by 2030, expanding at a CAGR of 9.4% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growth of the clinical laboratory tests market is attributable to the rising prevalence of target diseases. The use of clinical laboratory tests is on a rise owing to the use of tests in a wide variety of diagnostic purposes that primarily focus on patient health leading to evaluating and formulating proper diagnosis and treatment.

The global geriatric population is increasing and is considered as being the greatest risk factor for the development of conditions, such as cardiovascular diseases and kidney dysfunction. According to WHO, the population aged above 60 years is expected to be 1 in every 6 people by 2030, which accounts for an increase from 1 billion in 2020 to 1.4 billion by 2030. In addition, the number of people aged 80 and above is projected to double to over 1.5 billion by 2050, and people aged above 80 years are expected to triple and reach 426 Billion. Thus, the growing geriatric population is expected to be a high-impact rendering driver for this market over the forecast period.

The growing prevalence of target diseases, such as CVD and diabetes, is anticipated to boost the market over the forecast period. CVD is fatal and leading cause of death worldwide. Presence of high unmet medical needs pertaining to cardiovascular diseases and the subsequent rise in patient awareness are among factors expected to boost the demand for point-of-care lipid testing. According to WHO, in 2021, cardiovascular diseases have been leading cause of mortality and morbidity worldwide in the last three decades, 17.7 Billion people die every year due to cardiovascular diseases, which is 31% of all the deaths worldwide.

Order your copy of Free Sample of “Clinical Laboratory Industry Data Book - Clinical Laboratory Tests and Clinical Laboratory Service Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

Clinical Laboratory Service Market Growth & Trends

The global clinical laboratory service market size is expected to reach USD 280.67 billion by 2030, registering a CAGR of 3.2% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the industry can be attributed to the increasing prevalence of the geriatric population, which, in turn, is propelling the demand for early disease diagnosis. The growing prevalence of target diseases, such as diabetes and Cardiovascular Diseases (CVDs), is a high impact-rendering driver for industry growth over the forecast period. Cardiovascular disease is the leading cause of death globally. The presence of unmet medical needs pertaining to disease management and the subsequent increase in patient awareness in more regions are expected to boost the demand for clinical laboratory testing.

Improvements in laboratory testing technology through breakthrough and incremental advances are high-impact-rendering drivers for industry growth. Market firms are engaged in introducing new services to serve the unmet demand of patients. For instance, in May 2022, Hamilton County entered into a partnership with Ethos Laboratories for the launch of no-cost COVID-19 testing sites. In July 2022, Mayo Clinic laboratories launched monkeypox tests to increase availability and accessibility to a wider target population. Moreover, in January 2022, Quest Diagnostics launched COVID-19 rapid antigen tests available through QuestDirect in collaboration with eMed to provide access to testing for COVID-19 at home. The pandemic affected millions of people globally. According to the CDC and WHO, the standard for diagnosis of COVID-19 is RT-PCR for samples from the respiratory tract.

The adoption of PCR technology for the diagnosis of COVID-19 and the genetic sequencing of the virus for the development of a cure is driving the industry. Due to this pandemic, there is an increase in the approval of tests for the diagnosis of the novel coronavirus, with most of these tests approved under Emergency Use Authorization (EUA) by federal agencies. Furthermore, the industry operates through different sales channels—laboratories and hospitals. The presence of prominent players in various regions is expected to drive the industry. For instance, in February 2022, Labcorp entered a comprehensive partnership with Ascension. Through this collaboration, Labcorp will handle Ascension’s hospital-based labs situated in ten states for buying assets for its outreach laboratory business.

Go through the table of content of Clinical Laboratory Industry Data Book to get a better understanding of the Coverage & Scope of the study.

Competitive Landscape

Key players operating in the Clinical Laboratory Industry are –
• Abbott
• ARUP Laboratories
• OPKO Health, Inc.
• Bioscientia Healthcare GmbH
• Charles River Laboratories
• NeoGenomics Laboratories
• Healthscope
• Labco
• Laboratory Corporation of America Holdings
• Fresenius Medical Care AG & Co. KGaA
• QIAGEN
• Quest Diagnostics Incorporated
• Siemens Healthcare GmbH
• Tulip Diagnostics (P) Ltd
• Sonic Healthcare Limited
• Merck KGaA
• Biosino Bio-Technology and Science Inc.
• Cinven
• DaVita Inc.
• SGS Société Générale de Surveillance SA
• Almac Group

Grand View Research’s Clinical Laboratory Industry data book is a collection of market sizing information & forecasts, regulatory data, competitive benchmarking analyses, macro-environmental analyses, and technological framework studies. Within the purview of the database, all such information is systematically analyzed and provided in the form of presentations and detailed outlook reports on individual areas of research.

Check out more Industry Data Books, published by Grand View Research

About Grand View Research

Wednesday 16 August 2023

Cancer Diagnostics Industry Data Book | Trends, Analysis And Segment Forecasts, 2023 - 2030

Cancer Diagnostics Industry Data Book Covers Breast Cancer Diagnostic, Cervical Cancer Diagnostic, Lung Cancer Diagnostic, Liver Cancer Diagnostic, Pancreatic Cancer Diagnostic and Ovarian Cancer Diagnostic Markets.

The global cancer diagnostics market is combined to account for USD 45.66 billion revenue in 2022, which is expected to reach USD 89.02 billion by 2030, growing at a cumulative rate of 5.97% over the forecast period.

Access the Global Cancer Diagnostics Industry Data Book, 2023 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competitive benchmarking, macro-environmental analyses, and regulatory & technological framework studies.

Breast Cancer Diagnostics Market Growth & Trends

The global breast cancer diagnostics market size is expected to reach USD 6.8 billion by 2028, according to a new study by Grand View Research Inc. The market is expected to expand at a CAGR of 7.0% from 2021 to 2028. The growth is largely attributable to the increasing geriatric population exposed to the risk of breast cancer and early detection coupled with increasing awareness about breast cancer.

The introduction of 3D mammography or digital breast tomosynthesis, which is more accurate than 2D mammography, supports market growth. This advanced technology can detect 40.0% more cancers than 2D mammograms and reduce patient recalls. Rapid technological advancements are a major factor expected to drive the market over the coming years.

Cervical Cancer Diagnostic Market Growth & Trends

The global cervical cancer diagnostic market was valued at USD 7 billion in 2015 and is expected to reach a value of USD 12 billion by 2024, according to a new report by Grand View Research, Inc. The key driving factors include the rising prevalence of cervical cancer, evolving screening technology, and various programs that promote routine check up and screening. According to the data published by the WHO, in 2012, over 270,000 women died due to cervical cancer, majority of which were from the developing countries. It is one of the most common cancer type diagnosed in women. Some of the etiological factors are multiple sex partners, and changing lifestyle, such as drinking & smoking and increased stress levels.

Furthermore, favorable government initiatives and increasing number of awareness programs are further expected to promote the market growth in coming few years. The National Cervical Cancer Coalition, WHO, CDC, the U.S. Preventive Services Task Force, are working towards promoting the necessity for early screening of cervical cancer amongst mid aged women.

Lung Cancer Diagnostics Market Growth & Trends

The global lung cancer diagnostics market is expected to reach USD 3,644.6 million by 2024, according to a new report by Grand View Research Inc. The development of lung cancer-specific biomarkers is one of the primary factors for the growth of the lung cancer diagnostics market over the forecast period. These diagnostic tools facilitate the personalized treatment approach of lung malignancies.

Various biomarkers are present in the research pipeline. For instance, in November 2015, Epigenomics AG announced the launch of a new blood-based test using DNA methylation biomarkers, the development of which is underway. The initial results of this test revealed a promising outcome in the early diagnosis of lung cancer.

Order your copy of Free Sample of “Cancer Diagnostics Industry Data Book - Breast Cancer Diagnostic, Cervical Cancer Diagnostic, Lung Cancer Diagnostic, Liver Cancer Diagnostic, Pancreatic Cancer Diagnostic and Ovarian Cancer Diagnostic Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

Pancreatic Cancer Diagnostic Market Growth & Trends

The global pancreatic cancer diagnostic market size is expected to reach USD 3.90 billion by 2030, according to a new report by Grand View Research, Inc. Furthermore, the industry is expected to expand at a CAGR of 6.53% over the forecast period. The introduction of innovative products, coupled with the rising need for early disease diagnosis and increasing research activities to develop advanced diagnostic solutions, is anticipated to drive the global market.

For instance, in August 2021, Immunovia, Inc. received approval from the Massachusetts Department of Public Health to start testing patients for pancreatic cancer, using the IMMray PanCan-d test. It is a laboratory-developed test for the early detection of pancreatic cancer. The market is projected to witness lucrative growth opportunities owing to increased research funding, technological advancements in diagnostic tests, and rising efforts from manufacturers to develop precise testing solutions. For instance, in December 2022, Bluestar Genomics, Inc. announced the initiation of one of the largest clinical trials for the early detection of pancreatic cancer.

Ovarian Cancer Diagnostics Market Growth & Trends

The global ovarian cancer diagnostics market size is expected to reach USD 2 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 6.2%. The growth of the market can be attributed to an increase in the prevalence of ovarian cancer and emergence of novel diagnostic products. As of 2018, ovarian cancer had the highest mortality rate of all gynecologic cancers. It accounted for nearly 14,000 deaths in the U.S. in 2018. No specific symptoms render early diagnosis of the disease increasingly difficult. The exact causative factors remain unknown, creating a key unmet need for further research to obtain clarity on the underlying molecular mechanisms.

Go through the table of content of Cancer Diagnostics Industry Data Book to get a better understanding of the Coverage & Scope of the study.

Liver Cancer Diagnostics Market Growth & Trends

The global liver cancer diagnostics market size is expected to reach USD 14.67 billion by 2030, advancing at a CAGR of 6.67% over the forecast period from 2023 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of liver cancer, the technological advancements for diagnosis, and the awareness of screening importance for treatment & survival rate are driving the market growth for liver cancer diagnostics.

According to the American Society of Cancer statistics in 2022, around 41,260 new cases are expected to be diagnosed with liver cancer. It was also presented by Globocan in 2020, that about 830,180 deaths were accounted by liver cancer worldwide. WHO also estimates that chronic hepatitis viral infections are widespread in the population, with hepatitis C virus (HCV) affecting about 58 million people. HCV and hepatitis B virus (HBV) are the most commonly associated risk factors of liver cancer. In addition, the infection prevalence and exposure to other risk factors such as cirrhosis and smoking will upsurge the demand for screening solutions for early treatment & diagnosis of liver cancer to increase the survival rate. Thus, the demand for diagnostics products will boost during the forecast period, thereby driving market growth.

Competitive Landscape

Key players operating in the Cancer Diagnostics Industry are –

• GE Healthcare
• Abbott
• F. Hoffmann-La Roche Ltd.,
• QIAGEN
• BD
• Siemens Healthcare GmbH,
• Thermo Fisher Scientific; Inc.
• Hologic, Inc.
• Koninklijke Philips N.V. (Philips)
• IIumina, inc.

Grand View Research’s Cancer Diagnostics industry data book is a collection of market sizing information & forecasts, regulatory data, competitive benchmarking analyses, macro-environmental analyses, and technological framework studies. Within the purview of the database, all such information is systematically analyzed and provided in the form of presentations and detailed outlook reports on individual areas of research.

Check out more Industry Data Books, published by Grand View Research

About Grand View Research

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com/sector-reports-list

Monday 14 August 2023

Antibodies Industry To Rise Up Due To The Increasing Awareness And Adoption Of Personalized Medicine

Grand View Research’s Antibodies industry data book is a collection of market sizing information & forecasts, regulatory data, competitive benchmarking analyses, macro-environmental analyses, and technological framework studies. Within the purview of the database, all such information is systematically analyzed and provided in the form of presentations and detailed outlook reports on individual areas of research.

Access the Global Antibodies Industry Data Book, 2023 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competitive benchmarking, macro-environmental analyses, and regulatory & technological framework studies.

Antibody Production Market Growth & Trends

The global antibody production market size is anticipated to reach USD 42.86 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.92% from 2023 to 2030. Due to the rising incidence of chronic illnesses such as cancer, diabetes, and cardiovascular diseases, as well as the increased need for therapeutic antibodies the antibody production market is anticipated a significant growth.

Nearly half of all R&D programs related to monoclonal antibodies are allocated for cancer treatment. The focused approach of monoclonal antibodies has transformed cancer treatment by minimizing adverse effects and enhancing patient outcomes. Nevertheless, further research and development are crucial to maximize the effectiveness of antibodies in treating cancer. The market for antibody production is anticipated to experience growth due to the escalated investment in research and development activities, particularly in cancer treatment. Moreover, the demand for personalized medicine, which seeks to offer customized treatments based on an individual's genetic composition, lifestyle, and environmental influences, is anticipated to boost the antibody production market's growth.

Polyclonal Antibodies Market Growth & Trends

The global polyclonal antibodies market size is anticipated to reach USD 2.21 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.01% from 2023 to 2030. The increasing technological advancements in the production of antibodies-based drugs, the growing prevalence of infectious & chronic diseases such as cancer across the globe, and the rising number of biopharmaceutical research and development activities are the main drivers of the industry. In addition, Polyclonal antibodies (pAbs) are extensively utilized in both quantitative and qualitative biological research as well as several diagnostic tests.
The use of polyclonal antibodies has had a positive impact on the treatment of COVID-19 patients, with studies showing that these therapies can reduce hospitalization rates and improve outcomes for patients with mild to moderate disease. Additionally, the development of pAbs has helped to advance the understanding of the immune response to COVID-19 and is projected to lead the development of more effective treatments and vaccines in the future. Thus, the COVID-19 pandemic has had a significant impact on the pAbs market.

Monoclonal Antibodies Market Growth & Trends

The global monoclonal antibodies market is projected to reach USD 494.53 billion by 2030, at a compound annual growth rate (CAGR) of 11.04% in the forecast period, according to a new report by Grand View Research, Inc. Increasing research and development activities aimed at the development of novel therapeutic monoclonal antibodies (mAbs) and supportive government initiatives for biologics production are anticipated to drive the market growth in the forecast period.

The rising demand for personalized medicine is likely to positively affect the development of therapeutic mAb targeted therapies that are tailored to individual requirements. Moreover, the therapeutic use of mAbs offers several advantages such as fewer adverse effects, specificity of treatment, and large-scale production capabilities, as compared to conventional treatment options, and can significantly drive market growth.

Order your copy of Free Sample of “Antibodies Industry Data Book - Antibodies Production, Polyclonal Antibody, Monoclonal Antibody, Cancer Monoclonal Antibody, Research Antibody, Custom Antibody, Mammalian IgG Polyclonal Antibody Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

Cancer Monoclonal Antibodies Market Growth & Trends

The global cancer monoclonal antibodies market size is expected to reach USD 281.78 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 18.20% from 2023 to 2030. The increasing prevalence of cancer, and product approvals along with a robust pipeline are the key factors augmenting the market growth. Furthermore, an increase in funding for R&D in this sector is expected to impact industrial growth. Moreover, the booming biosimilar market will further offer lucrative opportunities during the forecast period.

Non-small Cell Lung Cancer (NSCLC) is a common type of lung cancer. For patients with metastatic NSCLC, the prognosis is mostly poor, as only about 8% will live beyond 5 years after the diagnosis. Moreover, at present, there are no HER2-directed therapies approved precisely for treating HER2-mutant non-small cell lung cancer, which occurs in almost 2-4% of patients with non-squamous NSCLC. However, progress has been made over the last two years, mainly in the first-line setting, leaving a substantial unmet medical need. For instance, in April 2022, Daiichi Sankyo and AstraZeneca received acceptance of supplemental Biologics License Application (sBLA) of Enhertu in the U.S. for treating adult patients with unresectable NSCLC.

Research Antibodies Market Growth & Trends

The global research antibodies market size is expected to reach USD 2.21 billion by 2030, expanding at a CAGR of 4.76% from 2023 to 2030, according to a new report by Grand View Research, Inc. Factors driving the market include a rise in R&D activities undertaken by biopharmaceutical and biotechnology companies and increase in support from government authorities. Furthermore, expansion in the scope of neurobiology and stem cell research and the availability of technologically advanced antibody production methods are expected to propel market growth.

An increase in the number of collaborative initiatives undertaken by research institutes and various public and private entities for the promotion of cell-based research is fueling market growth. The trend is more prominent in established markets, such as North America, that have an established scientific infrastructure. For instance, in March 2020, the Canadian government invested around USD 4.3 million in funds towards the Centre for Commercialization of Regenerative Medicine, which is involved in carrying out scientific studies based on cell regeneration. Moreover, in April 2021, the government announced an investment of USD 45 million over 3 years in Stem Cell Network to develop information, therapies, and technologies to benefit individuals living with chronic and severe illnesses such as COVID-19 and assess its long-term impact. Such initiatives are expected to encourage further adoption of antibody activities and enhance the growth prospects for the market.

Custom Antibody Market Growth & Trends

The global custom antibody market size is expected to reach USD 301.7 million by 2030, expanding at a CAGR of 9.7% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is expected to witness substantial growth during the forecast period. This growth is attributed to the increasing fundraising by biotech startups for developing innovative products. Additionally, rising awareness of personalized diagnostic and therapeutic treatments in emerging markets is also a contributing factor to the growth of the custom antibody market.

Increasing investment by the players to expand their services in the development and production of antibodies is likely to support the growth of the market. For instance, Absolute Antibody Ltd. is into the services of custom antibody sequencing, expression, and engineering. In August 2022, the company announced the expansion of its manufacturing facility by increasing the lab space and investing in automated technology such as next-generation sequencing, purification, and expression. The expansion is expected to improve the production workflow for recombinant antibodies.

Go through the table of content of Antibodies Industry Data Book to get a better understanding of the Coverage & Scope of the study.

Mammalian Polyclonal IgG Antibody Market Growth & Trends

The global mammalian polyclonal IgG antibody market size is expected to reach USD 1.67 billion by 2030, registering a CAGR of 5.01% of the overall revenue, according to a new report by Grand View Research, Inc. The industry has witnessed significant growth owing to the development of innovative drugs and increasing government initiatives. Pharma and biotech companies are indulging in rigorous research and development since the antibody-drug conjugate is considered to be the fastest-growing field of the pharmaceutical market.In October 2022, SAB Biotherapeutics announced an exclusive partnership with Emergent BioSolutions Inc. According to the agreement, Emergent BioSolutions is expected to offer end-to-end services of Contract Development and Manufacturing (CDMO) to produce polyclonal antibody-based products.

The partnership will enable SAB Biotherapeutics to primarily focus on the research and development of the polyclonal antibody drug pipeline. As of October 2022, the company is conducting various clinical-stage programs in the treatment of influenza, acute and recurrent C. diff., Type 1 diabetes and researching potential candidates in oncology and immunology. The COVID-19 pandemic surged the use of polyclonal antibodies across the globe. For instance, in July 2022, GigaGen Inc. announced the publication of research showcasing its studies of GIGA-2050, recombinant polyclonal antibodies for COVID-19. According to the research, the GIGA-2050 has an effective manufacturing approach to treating infectious diseases by targeting numerous viral epitopes.

Competitive Landscape

Key players operating in the Antibodies Industry are –

• Danaher Corporation
• Thermo Fisher Scientific Inc.
• Sartorius AG
• GE Healthcare
• Eppendorf AG
• Merck KGaA
• Amgen Inc
• Novartis AG
• AstraZeneca plc
• Abcam plc
• F. Hoffman-La Roche Ltd.
• Eli Lilly and Company

Check out more Industry Data Books, published by Grand View Research

About Grand View Research

Sunday 13 August 2023

Livestock Artificial Insemination Industry To Evolve Due To The Need For Genetic Improvement Shape Its Landscape

Friday 11 August 2023

Life Science Microscopes Industry Data Book | Analysis And Segment Forecasts, 2022 – 2030

Life Science Microscopes Industry Data Book Covers Surgical, In-vitro Fertilization, Super Resolution and Scanning Electron Microscopes Markets.

The global life science microscopes industry generated over USD 3.35 billion in 2021 and is expected to grow at a CAGR of 8.9% over the forecast period.

Access the Global Life Science Microscopes Industry Data Book, 2022 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competitive benchmarking, macro-environmental analyses, and regulatory & technological framework studies.

Surgical Microscopes Market Growth & Trends

The global surgical microscopes market size is expected to reach USD 2.9 billion by 2030, growing at a CAGR of 11.35% from 2023 to 2030, based on a new report by Grand View Research, Inc. With the advent of surgical microscopes, it became easier for surgeons to perform such procedures more accurately in less time. In addition, the introduction of technologically advanced products is driving the demand for surgical microscopes as they are more precise, offer better illumination sources, and provide options for customization and technology integration based on the complexity of the procedures.

Emerging technologies such as wide-angle illumination, Red Reflex illumination, automation and augmented reality microscopy are expected to boost the market growth. International players like Carl Zeiss Meditec AG and Leica Microsystems are contributing to the market by providing highly advanced, automated, and robotic surgical microscopes for more precision.

In-vitro Fertilization Microscopes Market Growth & Trends

The global In-Vitro fertilization microscopes market size is expected to reach USD 193.2 million by 2030, expanding at 8.41% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. In-vitro fertilization (IVF) microscopes are integral equipment used in any IVF lab. These microscopes have applications such as embryo assessment, and sperm selection. Thereby, advancements in microscopes and microscope-related equipment in in-vitro fertilization are expected to drive market growth.

Manufacturers are providing upright microscopes, digital microscope cameras, and software to view images together as part of a sperm analysis system to provide the complete solution for semen analysis. Moreover, as sperm analysis can be better studied by maintaining a certain temperature of the sample, manufacturers are coupling the use of such devices with an upright microscope. For instance, CooperSurgical offers andrology microscopes solutions for IVF labs. This microscope enables the assessment of the quantity and quality of the sperm. These microscopes ideally come with phase contrast and cold LED illumination. It embeds high-resolution, high-contrast imaging; ensuring the safety of the samples.

Order your copy of Free Sample of “Life Science Microscopes Industry Data Book - Surgical, In-vitro Fertilization, Super Resolution And Scanning Electron Microscopes Market Size, Share, Trends Analysis And Segment Forecasts, 2022 - 2030” Data Book, published by Grand View Research

Super-resolution Microscopes Market Growth & Trends

The global super-resolution microscopes market size is expected to reach USD 6.6 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 9.04% from 2023 to 2030. Increasing application in cell biology and biomedical imaging is a key factor expected to drive the market over the forecast period.

Governments all over the world are supporting R&D for innovative technology, majorly nanotechnology research to help build improved nanoimaging technology-based super-resolution microscopes. The National Institutes of Health in the U.S. established a trans-NH bioengineering nanotechnology program to solicit grant applications for biomedical nanotechnologies. The U.K. government spent EUR 81 million (USD 105 million) on the development of advanced 3D imaging technology in February 2020.

Scanning Electron Microscopes Market Growth & Trends

The global scanning electron microscopes market size is expected to reach USD 6.5 billion by 2028, registering a CAGR of 8.52% over the forecast period, according to a new report by Grand View Research, Inc. Rising demand for nanotechnology-based research and growing R&D innovation in application areas are anticipated to serve as key growth drivers. Rapid growth witnessed in application areas, such as semiconductors, automobiles, pharmaceuticals, and nanotechnology, globally is among the key factors responsible for the significant growth of the SEM market.

Technological advancements in SEM improves the quality control procedures of research laboratories in a wide range of industries, such as semiconductors, automobiles, and pharmaceutical manufacturing. Scanning electron microscopy plays a critical role in the imaging and elemental analysis of products. However, the advanced SEMs offer advantages, such as rapid analysis, compact size, and efficient results with higher resolution and 3D imaging. Furthermore, the COVID-19 pandemic is expected to increase the sale of SEMs.

Go through the table of content of Life Science Microscopes Industry Data Book to get a better understanding of the Coverage & Scope of the study.

Competitive Landscape

Key players operating in the Life Science Microscopes Industry are –

• Carl Zeiss Meditec AG
• Leica Microsystems
• Olympus Corporation
• Nikon Corporation
• Applied Precision (GE Healthcare)
• Haag-Streit Surgical GmbH
• Synaptive Medical
• Alcon, Inc. (Novartis)
• Topcon Corporation
• ARI Medical Technology Co., Ltd.
• Takagi Seiko Co., Ltd.
• Seiler Instrument Inc.
• Chammed Co. Ltd

Grand View Research’s Life Science Microscopes Industry data book is a collection of market sizing information & forecasts, regulatory data, competitive benchmarking analyses, macro-environmental analyses, and technological framework studies. Within the purview of the database, all such information is systematically analysed and provided in the form of presentations and detailed outlook reports on individual areas of research.

Check out more Industry Data Books, published by Grand View Research

About Grand View Research

Thursday 10 August 2023

Active Pharmaceutical Ingredients (API) and High Potency API (HPAPI) Data Book | Research Report to 2030

Active Pharmaceutical Ingredients and High Potency API Industry Data Book Covers Active Pharmaceutical Ingredients and High Potency Active Pharmaceutical Ingredients Markets.

The global active pharmaceutical ingredients market was valued at USD 209.71 billion in 2021 and is anticipated to witness growth at a rate of 5.9% over the forecast period. The global high potency API market was valued at USD 23.60 billion in 2021 and is anticipated to witness growth at a rate of 6.2% over the forecast period.

Access the Global Active Pharmaceutical Ingredients and High Potency API Industry Data Book, 2023 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competitive benchmarking, macro-environmental analyses, and regulatory & technological framework studies.

Active Pharmaceutical Ingredients Market Growth & Trends

The global active pharmaceutical ingredients market size is expected to reach USD 352.98 billion by 2030, expanding at a compound annual growth rate (CAGR) of 6.0% during the forecast period, according to a new report by Grand View Research, Inc. The market is driven by the growth of the biopharmaceutical sector, advancements in active pharmaceutical Ingredients (API) manufacturing, and an increase in the geriatric population.

The growth of the captive API segment is propelled by companies investing in solving challenges and developing new chemical ways for the production of APIs in-house. This aids in reducing costs and the risk of contamination. Artificial intelligence and protein synthesis are expected to facilitate faster development with greater control over the process.

The rising prevalence of chronic and lifestyle-based conditions, such as cardiovascular diseases, is accelerating the demand for API. For instance, as per U.S. Pharmacist in 2020, 47% of adults have at least one risk factor that supports cardiovascular disease development. Cardiovascular diseases are one of the global, critical public health burdens driving extensive R&D for APIs in the field.

The active pharmaceutical Ingredients market was positively influenced by the COVID-19 pandemic, as countries and significant players produce large quantities of components to meet the demand for the treatment of COVID-19. As a result of the outbreak, drug companies have changed the companies’ strategies to focus on a larger patient population. To treat coronavirus, the U.S., for example, requested that HCQ be imported from India. The virus has also impacted Canada's medicine supply system, potentially causing complications for patients. The increasing importance of generics, rise in consumption of biopharmaceuticals, and expanding drug research and development activities for drug manufacturing are the primary drivers driving the growth of the market. However, the market's expansion is likely to be hampered by unfavourable drug price control regimes in several countries and high manufacturing costs.

Order your copy of Free Sample of “Active Pharmaceutical Ingredients and High Potency API Industry Data Book - Active Pharmaceutical Ingredients and High Potency Active Pharmaceutical Ingredients Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030” Data Book, published by Grand View Research

High Potency Active Pharmaceutical Ingredients Market Growth & Trends

The global high potency active pharmaceutical ingredients market size is expected to reach USD 40.66 billion by 2030 and is expected to expand at a compound annual growth rate (CAGR) of 6.2% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the HPAPI market is attributed to rising incidence of cancer, growing targeted therapies, and increasing application of high potency active pharmaceutical ingredients (HPAPI) in treating target diseases. Rising prevalence of cancer is expected to be a major factor. According to the WHO, cancer is the second leading cause of death, accounting for around 9.9 million deaths in 2020. Due to the growing number of people who contract the disease, cancer is regarded as one of the major health risks. The CDC states that factors such as smoking, obesity, alcohol use, and UV radiation exposure are risk factors for cancer since they contribute to the overall burden of the illness.

With limited treatment options and side effects associated with chemotherapy, there is a rising popularity of targeted therapy as it does not damage non-cancerous cells. In May 2021, Amgen, Inc. received the U.S. FDA approval for the launch of LUMAKRAS for treating patients with KRAS G12C-mutated locally advanced or metastatic NSCLC. LUMAKRAS is the first targeted product for the treatment of G12C-mutated KRAS NSCLC patients. This is likely to increase the demand for HPAPIs in the coming years. Characteristics of these anti-cancerous drugs, such as minimum exposure of drugs to non-cancerous cell and their effectiveness, are contributing to market growth.

The proprietary technology of companies, such as drug designing & delivery technology helps develop novel treatment and HPAPI alternatives through collaborations with other key players, which may increase the number of research initiatives. For instance, in November 2021, the company launched a novel technology ChetoSensar to enhance the development of Antibody–Drug Conjugates (ADCs) therapies. This initiative is aimed at significantly doubling the company’s efforts to boost its production of HPAPIs and ADCs.

Go through the table of content of Active Pharmaceutical Ingredients and High Potency API Industry Data Book to get a better understanding of the Coverage & Scope of the study.

Competitive Landscape

Key players operating in the Active Pharmaceutical Ingredients and High Potency API Industry are –

• Novo Nordisk
• Merck KGaA
• Novartis AG
• Aurobindo Pharma
• Piramal Pharma
• Teva Pharmaceutical Industries Ltd.
• AbbVie, Inc.
• BASF SE
• Boehringer Ingelheim International GmbH
• CordenPharma
• Merck & Co., Inc.
• Dr. Reddy’s Laboratories Ltd.
• Cipla, Inc.
• Bristol-Myers Squibb Company
• Sun Pharmaceutical Industries Ltd.
• Sanofi
• Pfizer, Inc.
• Viatris Inc.
• Albemarle Corporation
• Aurobindo Pharma

Grand View Research’s Active Pharmaceutical Ingredients and High Potency API industry data book is a collection of market sizing information & forecasts, regulatory data, competitive benchmarking analyses, macro-environmental analyses, and technological framework studies. Within the purview of the database, all such information is systematically analyzed and provided in the form of presentations and detailed outlook reports on individual areas of research.

Check out more Industry Data Books, published by Grand View Research